October 3, 2025
Daljeet Kohli
Daljeet Kohli of IndiaNivesh is acknowledged as an authority on the Pharma sector. He understands the sector very well and knows what makes each stock tick. His latest stock recommendations require to be paid attention to by us
Daljeet Kohli of IndiaNivesh is acknowledged as an authority on the Pharma sector. He understands the sector very well and knows what makes each stock tick. His latest stock recommendations require to be paid attention to by us




If you wake up Daljeet Kohli in the middle of the night and ask him to recommend a stock, he will in all probability blurt out the name of a Pharma stock. Why? Because, Daljeet has a deep understanding of the sector and has mastered all the nuances that affect the stocks in that sector.

It is no surprise that Daljeet has attained the maximum success in his career with Pharma stocks.

From a 10-bagger in Ajanta Pharma (in just 3 years) to stupendous gains in Alembic Pharma and JB Chemicals tells you everything you need to know about Daljeet’s stock picking prowess.

Even newcomer stocks like Sharon Bio-Medicine and Aurobindo Pharma, which were unceremoniously recommended by Daljeet, thrilled his followers with hefty quick-fire returns in just a couple of months.

In his latest report, Daljeet has carried out a careful analysis of his favourite stocks and offered clear-cut recommendations on what we should do with them.

Out of the 17 stocks listed in the report, only 7 have been awarded the coveted recommendation of “Buy”. Of these, Sharon Bio-Medicine is claimed to have the highest target gains of 90%+. This is followed by JB Chemcicals with a 28% potential gain. Aurobindo Pharma comes third with a potential of 23% gain.

A detailed explanation in support of each recommendation is given.

One stock you need to pay special attention to is IPCA Labs. When a stock picker of the caliber of Sanjoy Bhattacharyya calls it a “great chance” to buy a “wonderfully run company, with a tremendous track record and high quality management”, you know you are in safe hands. Saurabh Mukherjea, whiz-kid with Ambit Capital, echoed the same sentiments. Several other savvy experts have also recommended a buy on the stock.

So, if you haven’t already, you need to read up Daljeet’s report and carefully ponder over your next move. After all, you don’t want to miss out on a chance of making a few hefty bucks, do you.

2 thoughts on “Are You Going To Act On Daljeet Kohli’s Advice On Pharma Stocks?

  1. Will never follow ppl like Daljeet . No great shakes this guy is…..all do well in booming mkt but he took investors to the cleaners with Sharon. Test of a guy is when in hot mkt he recommends something that turns around as a multibagger. Identifications need lot of hard work and no one is better or worst than any of the analysts except that study thoroughly and then invest. This guy is all crap….

  2. Recommendations for 2015:

    Geometric software: buy at 125 target 210

    Wipro. Buy at 550 target 621

    Exide buy at 175 target 214

    Unitech buy at 16 target 28

    Subros buy at 65 target 91.

    Note the above five and keep sending emails in case u need updates

    Happy investing in 2015….

    Cheers

Leave a Reply

Your email address will not be published. Required fields are marked *